Back to search

Article

Bevacizumab, Pembrolizumab, and Low-Dose Capecitabine in Refractory Metastatic Gastrointestinal Cancers: A Retrospective Real-World Analysis

2026-08-31

Abstract excerpt

<title>Abstract</title> <p>Background: Treatment options for patients with refractory advanced gastrointestinal malignancies remain limited, particularly for mismatch-repair proficient tumors with low sensitivity to immune-checkpoint inhibition. VEGF-mediated angiogenesis contributes to an immunosuppressive tumor microenvironment and may represent a rational target to enhance antitumor immunity. We retrospective...

Identifiers and source

Literature Corpus work
4cb43d42-431e-58d8-96b0-349ef558efc5
DOI
10.21203/rs.3.rs-10425463/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Bevacizumab, Pembrolizumab, and Low-Dose Capecitabine in Refractory Metastatic Gastrointestinal Cancers: A Retrospective Real-World AnalysisDOI 10.21203/rs.3.rs-10425463/v1
Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer.Semantic proximity
Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series.Semantic proximity
Effect of Antiangiogenic-Based Treatment and Systemic Inflammatory Factors on Outcomes in Patients With BRAF v600-Mutated Metastatic Colorectal Cancer: A Real-World Study in SpainSemantic proximity
From poor prognosis to precision promise: Clinical trials targeting BRAF-mutant metastatic colorectal cancer.Semantic proximity
Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 studySemantic proximity
The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Colorectal Cancer: A Systematic Review and Meta-AnalysisSemantic proximity
[What are the new therapeutic strategies in metastatic colorectal cancer including biotherapies?].Semantic proximity
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 studySemantic proximity
Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancerSemantic proximity
PD-1 Inhibitor Bests Chemo for Colorectal CancerSemantic proximity
Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.Semantic proximity
Clinical complete response to serplulimab plus bevacizumab and chemotherapy in MSS/KRAS-mutant metastatic sigmoid colon adenocarcinoma: a case report and literature review.Semantic proximity
Select a neighboring publication to make it the new centre.